TEG001 / Century Therap - LARVOL DELTA

FIRST IN HUMAN CLINICAL RESPONSES AND PERSISTENCE DATA ON TEG001: A NEXT GENERATION OF ENGINEERED ALPHA/BETA T-CELLS TARGETING AML AND MM WITH A GAMMA9DELTA2 TCR (EBMT 2023) - "Conditioning consisted of fludarabine i.v. 25 mg/m2 (day -4 to -2) and cyclophosphamide i.v. 900 mg/m2 (day -2). Pamidronate (PAM) (30 mg i.v.) was administered on day 0 and 28 to propagate TEG001 activity...AEs contributable to cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (iCANS) grade 3 responding to tocilizumab and/or steroids were not defined as DLT...The seizure responded well to levetiracetam and no other neurological signs associated with iCANS were observed... TEG001 cells are well-tolerated at the first 2 dose levels tested. TEG001 cells show persistence up to day 56. In the 5 AML patients, we observed 1 complete remission and 2 patients with stable disease."

Clinical • P1 data • Acute Myelogenous Leukemia • CNS Disorders • Epilepsy • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Multiple Myeloma • Myelodysplastic Syndrome • Novel Coronavirus Disease • Oncology

First in Human Clinical Responses and Persistence Data on TEG001: A Next Generation of Engineered Αβ T Cells Targeting AML and MM with a High Affinity γ9δ2TCR (ASH 2022) - "The conditioning regimen consisted of fludarabine i.v. 25 mg/m2 (day -4 to -2) and cyclophosphamide i.v. 900 mg/m2 (day -2). Pamidronate (PAM) (30 mg I.V.) was administered on day 0 and on day 28 to propagate TEG001 activity...AEs contributable to cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (iCANS) grade 3 responding to tocilizumab and/or steroids were not defined as a DLT.Result s :Fourteen patients were included...The seizure responded well to levetiracetam and no other neurological signs associated with iCANS were observed...J Immunother Cancer, 2019. 7(1): p. 69."

Clinical • P1 data • Acute Myelogenous Leukemia • CNS Disorders • Epilepsy • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Leukemia • Multiple Myeloma • Myelodysplastic Syndrome • Novel Coronavirus Disease • Oncology